Clinical Trial Update: Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial of natalizumab (BG00002, Tysabri) in Japanese participants with relapsing-remitting multiple sclerosis has completed and results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-10-21